HC Wainwright Has Optimistic Outlook of OBIO Q1 Earnings

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – HC Wainwright boosted their Q1 2026 earnings per share estimates for Orchestra BioMed in a report released on Monday, March 16th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.33) for the quarter, up from their previous estimate of ($0.42). The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Orchestra BioMed’s Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.40) EPS and FY2026 earnings at ($1.53) EPS.

Orchestra BioMed (NASDAQ:OBIO) last released its quarterly earnings data on Thursday, March 12th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.64. The company had revenue of $30.92 million during the quarter, compared to the consensus estimate of $0.93 million. Orchestra BioMed had a negative return on equity of 184.17% and a negative net margin of 157.40%.

Several other equities analysts also recently issued reports on the stock. TD Cowen initiated coverage on shares of Orchestra BioMed in a research note on Wednesday, December 10th. They set a “buy” rating for the company. Wall Street Zen raised shares of Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research note on Saturday. Barclays increased their price objective on Orchestra BioMed from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $13.80.

Orchestra BioMed Stock Up 1.3%

NASDAQ:OBIO opened at $4.61 on Wednesday. Orchestra BioMed has a one year low of $2.20 and a one year high of $5.42. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.45 and a quick ratio of 6.43. The company has a market cap of $269.78 million, a PE ratio of -4.08 and a beta of 0.56. The firm’s 50 day simple moving average is $4.20 and its 200 day simple moving average is $3.88.

Insider Activity

In other Orchestra BioMed news, insider David P. Hochman purchased 10,000 shares of Orchestra BioMed stock in a transaction that occurred on Friday, March 13th. The stock was acquired at an average price of $4.29 per share, with a total value of $42,900.00. Following the transaction, the insider owned 1,086,467 shares in the company, valued at $4,660,943.43. This trade represents a 0.93% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Orchestra BioMed

A number of hedge funds have recently added to or reduced their stakes in the stock. Catalyst Funds Management Pty Ltd purchased a new position in shares of Orchestra BioMed during the second quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. bought a new position in Orchestra BioMed during the fourth quarter valued at about $38,000. Creative Planning bought a new position in shares of Orchestra BioMed during the 2nd quarter valued at approximately $40,000. XTX Topco Ltd purchased a new stake in Orchestra BioMed in the second quarter worth $45,000. Finally, Jane Street Group LLC purchased a new stake in Orchestra BioMed in the 2nd quarter worth about $50,000. Institutional investors and hedge funds own 53.20% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.